Get startedLog in
    Picture of Silence Therapeutics logo

    SLNCF — Silence Therapeutics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMid CapMomentum Trap
    All News

    Brief: Silence Therapeutics And Mallinckrodt Initiate Work On Third Target As Part Of Ongoing RNAi Research Collaboration

    Picture of Silence Therapeutics logoSilence Therapeutics
    26/02/2021 12:11
    Feb 26 (Reuters) - Mallinckrodt PLC  MCDG.MU :
    * SILENCE THERAPEUTICS AND MALLINCKRODT INITIATE WORK ON
THIRD
TARGET AS PART OF ONGOING RNAI RESEARCH COLLABORATION FOR
COMPLEMENT-MEDIATED DISEASES
    * SILENCE THERAPEUTICS PLC - SILENCE TO RECEIVE $2 MILLION
RESEARCH MILESTONE PAYMENT
    * SILENCE THERAPEUTICS PLC - ELIGIBLE TO RECEIVE UP TO $2
BILLION
IN TOTAL MILESTONE PAYMENTS ACROSS ALL 3 TARGETS
    * SILENCE THERAPEUTICS PLC - ELIGIBLE TO RECEIVE TIERED
DOUBLE-DIGIT ROYALTIES ON NET SALES FOR EACH PRODUCT CANDIDATE

Source text for Eikon:  ID:nGNX1ZSdz5 
Further company coverage:  MCDG.MU 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Silence Therapeutics

    See all news